Freestone Grove Partners’s Editas Medicine EDIT Stock Holding History

Freestone Grove Partners’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-36,126	Closed	-$45.9K	–	644
2024 Q4	$45.9K	Buy	+36,126	New	+$92K	﹤0.01%	569

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Freestone Grove Partners's EDIT Position: Q1 2025 in Review

Freestone Grove Partners sold out of Editas Medicine (EDIT) in Q1 2025, closing a stake of 36,126 shares — an estimated $45.9K sold.

Freestone Grove Partners first reported a position in EDIT in Q4 2024 and held it in 1 quarter. The position peaked at $45.9K in Q4 2024. 194 funds tracked by Wall St. Rank hold EDIT as of Q1 2025.

Freestone Grove Partners reported no remaining Editas Medicine position as of Q1 2025 after selling out during the quarter.
Freestone Grove Partners sold 36,126 Editas Medicine shares in Q1 2025, an estimated $45.9K.
Freestone Grove Partners first reported a position in Editas Medicine in Q4 2024 and held it in 1 quarter.
Freestone Grove Partners's Editas Medicine position peaked at $45.9K in Q4 2024.
194 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2025.

Based on Freestone Grove Partners's 13F filing for Q1 2025, filed 15 May 2025.